About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Found 848 record(s)
Req # A-2023-001173
Adverse Drug Reaction (ADR). Report number: E2B_02997619.Organization: Health Canada
February 2024
Req # A-2021-001996
Briefing notes and attachments regarding the January 17, 2022 authorization of PAXLOVID TM for patients with mild to moderate COVID-19 at high risk of developing serious disease from November 1, 2021 to February 1, 2022.Organization: Health Canada
February 2024
Req # A-2022-001027
The number of prescription requests for psychedelic drugs that were made and the number of prescriptions that were authorized by Health Canada since January 5, 2022.Organization: Health Canada
February 2024
Req # A-2023-000268
Module 5.2 (Tabular Listing of all Clinical Studies) for pms-Iron Sucrose that received a Notice of Compliance on 30 July 2020. Drug Identification Number (DIN) 02502917.Organization: Health Canada
February 2024
Req # A-2023-000395
The clinical trails for the premarket approval of the Selective Serotonin Reuptake Inhibitors (SNRI) antidepressant Effexor. The table of contents for all of those 12 paper volumes.Organization: Health Canada
February 2024
Req # A-2023-000716
All records pertaining to the medical relocations of Canadians facilitated or financed by the federal government from 2018 to August 20, 2024.Organization: Health Canada
February 2024
Req # A-2023-001153
A report/speadsheet showing the total number of consultant hired and all corresponding costs, broken down by department/agency and calendar year (2015 - 2023).Organization: Health Canada
February 2024
Req # A-2023-001188
A line listing in the Canada Vigilance Database of adverse reaction reports involving "copycat" edible cannabis products. Case reports made between the dates 01/01/2017 - 12/19/2023Organization: Health Canada
February 2024
Req # A-2023-001243
The number of applications for exemption under subsection 56(1) of the Controlled Drugs and Substances Act (CDSA) to possess and use psilocybin that were received by the Minister of Health in 2021, 2022 and 2023. The number of exemptions under subsection 56(1) of the Controlled Drugs and Substances Act (CDSA) to possess and use psilocybin that were issued by the Minister of Health in 2021, 2022 and 2023.Organization: Health Canada
February 2024
Req # A-2023-001244
The number of requests filed by medical practitioners on behalf of their patients to access psilocybin through Health Canada's Special Access Program (SAP) for emergency treatment of their patient in 2022, 2023, and 2024. The number of requests filed by medical practitioners on behalf of patients identifying as men and/or male to access psilocybin through Health Canada's Special Access Program (SAP) for emergency treatment of their patient in 2022, 2023, and 2024. The number of requests filed by medical practitioners on behalf of patients identifying as female and/or women to access psilocybin through Health Canada's Special Access Program (SAP) for emergency treatment of their patient in 2022, 2023, and 2024. The number of Special Access Program (SAP) requests filed by medical practitioners on behalf of their patients to access psilocybin for emergency treatment of their patient that were granted and/or approved in 2022, 2023, and 2024. The number of Special Access Program (SAP) requests filed by medical practitioners on behalf of patients identifying as men and/or male to access psilocybin for emergency treatment of their patient that were granted and/or approved in 2022, 2023, and 2024. The number of Special Access Program (SAP) requests filed by medical practitioners on behalf of patients identifying as female and/or women to access psilocybin for emergency treatment of their patient that were granted and/or approved in 2022, 2023, and 2024.Organization: Health Canada
February 2024